Fostering Innovative Technologies, Sustainable Solutions, and Social Development

RNA Sequence Design

Optimization and design of the CDS sequence, enhanced by artificial intelligence.
A proprietary UTR screening technology for the tailored design of UTRs in RNA sequences.
Incorporation of RNA secondary structure prediction tools to bolster RNA structural stability and translation efficiency.

i-Core LNP Technology for in vitro Cell Transfection

We have independently developed a proprietary third-generation ionizable lipid molecular library.
This library is complemented by a high-throughput biocomputing model designed for LNP formulation development.
Our innovative NeoLNP™ series of transfection products are designed for whole-cell line transfection, ensuring efficient transfection of immune cells and stem cells in vitro.

i-Core LNP Technology for in vivo Targeted Delivery

The i-Core LNP technology enables tissue-specific delivery via various routes of administration:
Hepatic Targeting (via Systemic Administration)
Pulmonary Targeting (via Nebulization)
Dermal Targeting (via Topical Administration)
Intellectual Property

Scindy Pharmaceutical (Suzhou) Co., Ltd.

Address: 6 / F, Block B, Building 4, No. 108 Yuxin Road, Suzhou Industrial Park, Suzhou, Jiangsu, P.R.China

Zip Code: 215125

Tel: +86 (512) 8886-5668

Email: service@scindypharm.com (For Sales)

Email: BD@scindypharm.com (For Cooperation)

【WeChat】
【Official Account】
Copyright © 2023 Scindy Pharmaceutical (Suzhou) Co., Ltd.        ICP NO.: 苏ICP备2021045264号-1